FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224228384> ?p ?o ?g. }

• W4224228384 endingPage "351" @default.
• W4224228384 startingPage "343" @default.
• W4224228384 abstract "<b><i>Background:</i></b> A phase 3 study to assess the efficacy and safety of the desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, against the epoetin alfa for the treatment of anemia in patients with chronic kidney disease (CKD) with dialysis dependency. <b><i>Methods:</i></b> DREAM-D was a phase 3, multicenter, open-label, randomized, active-controlled clinical study conducted across 38 centers in India. A total of 392 patients with clinical diagnosis of anemia due to CKD with dialysis need (Erythrocyte Stimulating Agent [ESA] naïve or prior ESA users) and with baseline hemoglobin levels of 8.0–11.0 g/dL (inclusive) were randomized in a 1:1 ratio to receive either desidustat oral tablets (thrice a week) or epoetin alfa subcutaneous injection for 24 weeks to maintain a hemoglobin level of 10–12 g/dL. The primary endpoint was to assess the change in the hemoglobin level between the desidustat and the epoetin alfa groups from the baseline to evaluation period week 16–24. The key secondary efficacy endpoint was the number of patients with hemoglobin response. <b><i>Results:</i></b> The least square mean (standard error) change in hemoglobin from the baseline to week 16–24 was 0.95 (0.09) g/dL in the desidustat group and 0.80 (0.09) g/dL in the epoetin alfa group (difference: 0.14 [0.14] g/dL; 95% confidence interval: −0.1304, 0.4202), which met the prespecified noninferiority margin. The number of hemoglobin responders was significantly higher in the desidustat group (106 [59.22%]) when compared to the epoetin alfa group (89 [48.37%]) (<i>p</i> = 0.0382). The safety profile of the desidustat oral tablet was comparable with the epoetin alfa injection. There were no new risks or no increased risks seen with the use of desidustat compared to epoetin alfa. <b><i>Conclusion:</i></b> In this study, desidustat was found to be noninferior to epoetin in the treatment of anemia in CKD patients on dialysis and it was well-tolerated. <b><i>Clinical Trial Registry Identifier:</i></b> CTRI/2019/12/022312 (India)." @default.
• W4224228384 created "2022-04-26" @default.
• W4224228384 creator A5005449480 @default.
• W4224228384 creator A5019021101 @default.
• W4224228384 creator A5025018452 @default.
• W4224228384 creator A5026735677 @default.
• W4224228384 creator A5031281958 @default.
• W4224228384 creator A5053827137 @default.
• W4224228384 creator A5057445675 @default.
• W4224228384 creator A5068370349 @default.
• W4224228384 creator A5071065356 @default.
• W4224228384 creator A5075430507 @default.
• W4224228384 creator A5083572894 @default.
• W4224228384 creator A5085823976 @default.
• W4224228384 creator A5087549969 @default.
• W4224228384 creator A5091412782 @default.
• W4224228384 date "2022-01-01" @default.
• W4224228384 modified "2023-09-25" @default.
• W4224228384 title "Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)" @default.
• W4224228384 cites W1893364029 @default.
• W4224228384 cites W1972566766 @default.
• W4224228384 cites W2010356452 @default.
• W4224228384 cites W2022451432 @default.
• W4224228384 cites W2041728941 @default.
• W4224228384 cites W2045516356 @default.
• W4224228384 cites W2047770739 @default.
• W4224228384 cites W2077357271 @default.
• W4224228384 cites W2082812841 @default.
• W4224228384 cites W2087377825 @default.
• W4224228384 cites W2106855201 @default.
• W4224228384 cites W2109126331 @default.
• W4224228384 cites W2148658873 @default.
• W4224228384 cites W2161071866 @default.
• W4224228384 cites W2407889154 @default.
• W4224228384 cites W2580449060 @default.
• W4224228384 cites W2593244426 @default.
• W4224228384 cites W2599499085 @default.
• W4224228384 cites W2614287697 @default.
• W4224228384 cites W2945654236 @default.
• W4224228384 cites W2964045421 @default.
• W4224228384 cites W3112489277 @default.
• W4224228384 doi "https://doi.org/10.1159/000523949" @default.
• W4224228384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35462369" @default.
• W4224228384 hasPublicationYear "2022" @default.
• W4224228384 type Work @default.
• W4224228384 citedByCount "11" @default.
• W4224228384 countsByYear W42242283842022 @default.
• W4224228384 countsByYear W42242283842023 @default.
• W4224228384 crossrefType "journal-article" @default.
• W4224228384 hasAuthorship W4224228384A5005449480 @default.
• W4224228384 hasAuthorship W4224228384A5019021101 @default.
• W4224228384 hasAuthorship W4224228384A5025018452 @default.
• W4224228384 hasAuthorship W4224228384A5026735677 @default.
• W4224228384 hasAuthorship W4224228384A5031281958 @default.
• W4224228384 hasAuthorship W4224228384A5053827137 @default.
• W4224228384 hasAuthorship W4224228384A5057445675 @default.
• W4224228384 hasAuthorship W4224228384A5068370349 @default.
• W4224228384 hasAuthorship W4224228384A5071065356 @default.
• W4224228384 hasAuthorship W4224228384A5075430507 @default.
• W4224228384 hasAuthorship W4224228384A5083572894 @default.
• W4224228384 hasAuthorship W4224228384A5085823976 @default.
• W4224228384 hasAuthorship W4224228384A5087549969 @default.
• W4224228384 hasAuthorship W4224228384A5091412782 @default.
• W4224228384 hasBestOaLocation W42242283841 @default.
• W4224228384 hasConcept C126322002 @default.
• W4224228384 hasConcept C203092338 @default.
• W4224228384 hasConcept C2776164570 @default.
• W4224228384 hasConcept C2778248108 @default.
• W4224228384 hasConcept C2778534260 @default.
• W4224228384 hasConcept C2778653478 @default.
• W4224228384 hasConcept C2778917026 @default.
• W4224228384 hasConcept C2779978075 @default.
• W4224228384 hasConcept C535046627 @default.
• W4224228384 hasConcept C71924100 @default.
• W4224228384 hasConcept C90924648 @default.
• W4224228384 hasConceptScore W4224228384C126322002 @default.
• W4224228384 hasConceptScore W4224228384C203092338 @default.
• W4224228384 hasConceptScore W4224228384C2776164570 @default.
• W4224228384 hasConceptScore W4224228384C2778248108 @default.
• W4224228384 hasConceptScore W4224228384C2778534260 @default.
• W4224228384 hasConceptScore W4224228384C2778653478 @default.
• W4224228384 hasConceptScore W4224228384C2778917026 @default.
• W4224228384 hasConceptScore W4224228384C2779978075 @default.
• W4224228384 hasConceptScore W4224228384C535046627 @default.
• W4224228384 hasConceptScore W4224228384C71924100 @default.
• W4224228384 hasConceptScore W4224228384C90924648 @default.
• W4224228384 hasIssue "5" @default.
• W4224228384 hasLocation W42242283841 @default.
• W4224228384 hasLocation W42242283842 @default.
• W4224228384 hasLocation W42242283843 @default.
• W4224228384 hasOpenAccess W4224228384 @default.
• W4224228384 hasPrimaryLocation W42242283841 @default.
• W4224228384 hasRelatedWork W1964706798 @default.
• W4224228384 hasRelatedWork W2014074349 @default.
• W4224228384 hasRelatedWork W2028422286 @default.
• W4224228384 hasRelatedWork W2040029744 @default.
• W4224228384 hasRelatedWork W2093825344 @default.
• W4224228384 hasRelatedWork W2130171323 @default.

• next